Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03185143 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea
A Phase 2 study, sponsored by Allodynic Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT03185143 is a Phase 2 study that has completed, run by Allodynic Therapeutics. The registered enrollment target is 36 participants.
The verdict
NCT03185143, a Phase 2 study, has completed, sponsored by Allodynic Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This proof-of-concept study compares side-by-side low-dose naltrexone and acetaminophen combination to sumatriptan in the acute treatment of migraine.
Interventions
- DRUG Placebo
- DRUG Sumatriptan 100 mg
- DRUG Naltrexone and Acetaminophen Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-06-27 |
| Est. Completion | 2018-05-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03185143
The ClinicalTrials.gov registry entry for NCT03185143 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allodynic Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03185143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03185143 about?
NCT03185143 is a clinical study titled "Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea". This proof-of-concept study compares side-by-side low-dose naltrexone and acetaminophen combination to sumatriptan in the acute treatment of migraine.
What is the current status of trial NCT03185143?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2017-06-27. Estimated completion is 2018-05-07.
What interventions are being tested in trial NCT03185143?
The interventions under investigation include: Placebo (DRUG), Sumatriptan 100 mg (DRUG), Naltrexone and Acetaminophen Combination (DRUG).
Who is sponsoring clinical trial NCT03185143?
This trial is sponsored by Allodynic Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.